SBI Securities’s Estrella Immunopharma ESLA Stock Holding History

SBI Securities’s Portfolio ESLA Stock Details ESLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-1	Closed	-$1	–	4094
2025 Q3	$1	Buy	+1	New	+$1	﹤0.01%	4170

Other funds holding ESLA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

SBI Securities's ESLA Position: Q4 2025 in Review

SBI Securities sold out of Estrella Immunopharma (ESLA) in Q4 2025, closing a stake of 1 share — an estimated $1 sold.

SBI Securities first reported a position in ESLA in Q3 2025 and held it in 1 quarter. The position peaked at $1 in Q3 2025. 15 funds tracked by Wall St. Rank hold ESLA as of Q4 2025.

SBI Securities reported no remaining Estrella Immunopharma position as of Q4 2025 after selling out during the quarter.
SBI Securities sold 1 Estrella Immunopharma share in Q4 2025, an estimated $1.
SBI Securities first reported a position in Estrella Immunopharma in Q3 2025 and held it in 1 quarter.
SBI Securities's Estrella Immunopharma position peaked at $1 in Q3 2025.
15 funds tracked by Wall St. Rank held Estrella Immunopharma as of Q4 2025.

Based on SBI Securities's 13F filing for Q4 2025, filed 3 Feb 2026.